A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The objective of this study is to compare the efficacy and safety between Mycamine and Itraconazole oral solution in preventing invasive fungal infections on autologous(malignant blood diseases) or allogeneic hematopoietic stem cell transplant patients
Condition or disease
Drug: micafungin (Mycamine)Drug: itraconazole
Dosing of Mycamine or Itraconazole will start at the beginning of the transplant conditioning regimen or within 48 hours after the transplant conditioning regimen, and administration time should be no longer than 42 days
A Multi-center, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of Mycamine® vs Itraconazole Oral Solution for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoietic Stem Cell Transplant
Study Start Date
Actual Primary Completion Date
Actual Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients at risk of systemic fungal infections due to their immunocompromised state due to one of the following:
Patient with a hematologic malignancy undergoing an autologous hematopoietic stem cell transplant
Any patient undergoing an allogeneic hematopoietic stem cell transplant
Patients with moderate or severe liver disease, as defined by:
AST or ALT greater than 5 times upper limit of normal (ULN), OR;
Total bilirubin greater than 2.5 times ULN
Patients with evidence of a deeply invasive or disseminated fungal infection at time of enrollment